6 registrations that name cerebrolysin as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 6 registrations
Status
Phase
All 6 registrations
RecruitingNCT05821075
Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy
Phase 1 and 2
October 6 University
About 90 people
Started Aug 24, 2023
In plain words A Phase 1 and 2 study of cerebrolysin in people 18 to 60, run by October 6 University. It plans to enroll about 90 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60. Conditions: Bell Palsy.
unilateral acute facial palsy of no identifiable cause
The exclusion criteria are on the listing.
What it tests, as registered
Prednisolone; Cerebrolysin
Registered summary
Bell's palsy, a peripheral facial nerve paresis, is the most common disorder of the facial nerve and one of the most common mononeuropathies. Many patients with Bell's palsy will develop some complications such as synkinesis, crocodile tears and 'sweating' of the ear while eating Commonly used medications to treat Bell's palsy is Corticosteroids Cerebrolysin stimulates the regeneration of the nervous tissue with protective action we aim to study the efficacy of cerebrolycin in Bell's palsy
Where, as registered
No US site; Egypt (1).
RecruitingNCT07043686
Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study
No phase
University Medical Centre Ljubljana
About 30 people
Started Jun 13, 2025
In plain words A study of cerebrolysin in people 18 and older, run by University Medical Centre Ljubljana. It plans to enroll about 30 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Ischemic Stroke, Acute; Rehabilitation Outcome; Cerebrolysin.
What it tests, as registered
Cerebrolysin treatment; Standard treatment (including neurorehabilitation) of acute ischemic stroke
Registered summary
The study evaluates the effect and safety of Cerebrolysin administered during early rehabilitation in patients with moderate neurological impairment after acute ischemic stroke, conducted at the Department of Vascular Neurology and Intensive Neurological Therapy, UMC Ljubljana.
Where, as registered
No US site; Slovenia (1).
RecruitingNCT04427241
Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness
Phase 4
Konkuk University Medical Center
About 12 people
Started Jun 1, 2023
In plain words A Phase 4 study of cerebrolysin in people 19 to 120, run by Konkuk University Medical Center. It plans to enroll about 12 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 19 to 120. Conditions: Disorder of Consciousness; Hemorrhagic Stroke.
Patients with hemorrhagic stroke confirmed by CT or MRI
Patients who have been in disorders of consciousness for more than 4 weeks after the onset of hemorrhagic stroke
Patients in a vegetative state or minimally conscious state (Coma Recovery Scale -revised: CRS-R assessment)
Age: 19 to 80 years of age
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Cerebrolysin; Control
Registered summary
Object: To determine the effect of cerebrolysin on prolonged disorders of consciousness caused by hemorrhagic stroke. Participants: patients with prolonged disorders of consciousness due to severe traumatic brain injury Intervention: 30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously or 100 ml normal saline, days 4-17, once/day, IV Comparison: cerebrolysin group versus control group Outcome: Coma Recovery Scale-revised, FDG-PET signal
Where, as registered
No US site; South Korea (1).
Not yet recruitingNCT07846488
Combined Acupuncture-Based Therapy for Rehabilitation After Ischemic Stroke
No phase
National Hospital of Acupuncture, Vietnam
About 440 people
Starts Dec 1, 2026 (estimated)
In plain words A study of cerebrolysin in people 18 and older, run by National Hospital of Acupuncture, Vietnam. It plans to enroll about 440 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Ischemic Stroke; Hemiplegia; Neurogenic Dysphagia.
Aged 18 years or older, regardless of sex and occupation.
Diagnosed with post-acute ischemic stroke.
Stabilized cardiovascular, respiratory, and neurological conditions, as well as vital signs following the acute phase.
Hemiplegia/Hemiparesis (motor deficit on one side of the body).
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Electro-Field Acupuncture; Electro-Acupuncture; Cerebrolysin; B complex vitamin; Acupressure Massage
Registered summary
Objective: To assess the therapeutic efficacy of combined electroacupuncture (or electric field acupuncture), hydroacupuncture (Cerebrolysin or B-complex vitamins), and acupressure massage in restoring motor function and treating dysphagia in post-acute ischemic stroke patients, while evaluating safety profiles and prognostic factors associated with clinical outcomes. The full summary is on the listing.
Where, as registered
No US site; Vietnam (1).
Not yet recruitingNCT06339411
Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy
Phase 2
Chang Gung Memorial Hospital
About 100 people
Starts Sep 1, 2026 (estimated)
In plain words A Phase 2 study of cerebrolysin in people 18 to 80, run by Chang Gung Memorial Hospital. It plans to enroll about 100 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Acute Ischemic Stroke.
Age 18 to 80 years.
Acute anterior-circulation ischemic stroke caused by internal carotid artery or M1 or M2 middle cerebral artery occlusion confirmed by computed tomography angiography.
Stroke onset-to-groin-puncture interval greater than 6 hours and no more than 24 hours.
Prestroke modified Rankin Scale score of 0 to 2.
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cerebrolysin; Normal saline placebo
Registered summary
Acute ischemic stroke caused by blockage of a large brain artery can lead to severe disability. Endovascular thrombectomy is a catheter-based procedure used to remove the blood clot and restore blood flow. It can benefit selected patients treated 6 to 24 hours after stroke onset, but some patients remain disabled even when the blocked artery is successfully reopened. Ongoing injury to brain tissue, small blood vessels, and the blood-brain barrier may contribute to this incomplete recovery. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT06899464
Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial
Phase 4
Cardinal Stefan Wyszynski University
About 30 people
Starts Oct 1, 2025 (estimated)
In plain words A Phase 4 study of cerebrolysin in people 18 to 80, run by Cardinal Stefan Wyszynski University. It plans to enroll about 30 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Intracerebral Hemorrhage; Hemorrhagic Stroke, Intracerebral; Hemorrhagic Stroke; Stroke.
Age 18-80 years
NIHSS ≥8 at randomization
Stroke onset <6h
Pre-randomization head CT demonstrating an acute, primary lobar ICH
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
14-day Cerebrolysin treatment; Standard of Care (SOC)
Registered summary
This study is designed to determine the safety and feasibility of using Cerebrolysin in treating primary intracerebral hemorrhage (ICH). This is a multicenter, prospective, randomized, open-label, blinded end-point, phase IV parallel group study done in specialized stroke treatment centers in Poland. The study objective is to evaluate if a 14-day cerebrolysin treatment initiated within 6 hours of onset of primary lobar hemorrhage in addition to the standard of care that includes early intensive rehabilitation is safe and feasible, affects hematoma growth and improves the outcome. The full summary is on the listing.